What question did this study set out to answer?

To assess whether distinct immunological profiles, including cytotoxic T-cell clones and Treg/Th17 ratios, correlate with long-term survival exceeding ten years in multiple myeloma.

September 13, 2013Blood Cancer JournalOpen Access

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

View Full Paper

Ask AI

Bookmark

Authors

CBChristian BryantRoyal Prince Alfred Hospital HSHayley SuenRoyal Prince Alfred Hospital RBRoss BrownEnvironment and Climate Change Canada

Discussion

Member takes

Overview

Observational study reveals distinct cytotoxic T-cell and Treg/Th17 profiles in ten-year multiple myeloma survivors, suggesting reduced immunosuppression supports exceptional longevity.

Key Points

To assess whether distinct immunological profiles, including cytotoxic T-cell clones and Treg/Th17 ratios, correlate with long-term survival exceeding ten years in multiple myeloma.
Analyzed peripheral blood samples to quantify cytotoxic T-cell clones, regulatory T cells (Tregs), and T helper 17 (Th17) cells.
Compared long-term survivors surviving >10 years (n=20) against multiple myeloma patients with <10 years follow-up (n=144) and age-matched healthy controls.
Measured the in vitro proliferative capacity of isolated cytotoxic T-cell clones across patient groups.
Cytotoxic T-cell clonal expansions were detected in 100% (n=19/19) of long-term survivors compared to 54% (n=144) of patients with shorter follow-up.
T-cell clones from long-term survivors demonstrated significantly higher in vitro proliferation than those from patients with shorter survival (median proliferation 61.5% vs. 6.1%, P < 0.0001).
Long-term survivors displayed significantly higher proportions of Th17 cells and lower frequencies of Tregs compared with standard-survival multiple myeloma patients.

Cite This Study

Bryant et al. (2013) studied this question.

synapsesocial.com/papers/69f8f331f3dd63f26c157208 https://doi.org/10.1038/bcj.2013.34

View Full Paper

Ask AI

Bookmark

September 13, 2013Blood Cancer JournalOpen Access

Long-term survival in multiple myeloma is associated with a distinct immunological profile, which includes proliferative cytotoxic T-cell clones and a favourable Treg/Th17 balance

View Full Paper

Ask AI

Bookmark

Authors

CBChristian BryantRoyal Prince Alfred Hospital HSHayley SuenRoyal Prince Alfred Hospital RBRoss BrownEnvironment and Climate Change Canada

Discussion

Member takes

Overview

Observational study reveals distinct cytotoxic T-cell and Treg/Th17 profiles in ten-year multiple myeloma survivors, suggesting reduced immunosuppression supports exceptional longevity.

Key Points

To assess whether distinct immunological profiles, including cytotoxic T-cell clones and Treg/Th17 ratios, correlate with long-term survival exceeding ten years in multiple myeloma.
Analyzed peripheral blood samples to quantify cytotoxic T-cell clones, regulatory T cells (Tregs), and T helper 17 (Th17) cells.
Compared long-term survivors surviving >10 years (n=20) against multiple myeloma patients with <10 years follow-up (n=144) and age-matched healthy controls.
Measured the in vitro proliferative capacity of isolated cytotoxic T-cell clones across patient groups.
Cytotoxic T-cell clonal expansions were detected in 100% (n=19/19) of long-term survivors compared to 54% (n=144) of patients with shorter follow-up.
T-cell clones from long-term survivors demonstrated significantly higher in vitro proliferation than those from patients with shorter survival (median proliferation 61.5% vs. 6.1%, P < 0.0001).
Long-term survivors displayed significantly higher proportions of Th17 cells and lower frequencies of Tregs compared with standard-survival multiple myeloma patients.

Cite This Study

Bryant et al. (2013) studied this question.

synapsesocial.com/papers/69f8f331f3dd63f26c157208 https://doi.org/10.1038/bcj.2013.34

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark